IPO and Other Stock Plays Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : IPO and Other Stock Plays

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: MLD38	6/13/2007 7:29:11 PM
	of 13331

IPO: Quark Pharmaceuticals, Inc. ( QURK ) ipohome.com Quark has a retail roadshow: retailroadshow.com Website quarkbiotech.com Management, etc: quarkbiotech.com Profile: hoovers.com Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Biotech is interested in. The drug development company is using cutting-edge RNA interference technology to develop siRNAs, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Biotech is developing other candidates for acute renal failure and hearing loss, and it has licensed BT16, a potential treatment for dyslipidemia, to Japanese drug firm Sanwa for development in Far East markets. Top competitors of Quark Biotech, Inc. (QURK Proposed) Genentech Novartis OSI Pharmaceuticals

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next